Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

368 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
Nagaoka T, Osumi H, Ueno T, Ooki A, Wakatsuki T, Nakayama I, Ogura M, Takahari D, Chin K, Matsueda K, Yamaguchi K, Shinozaki E. Nagaoka T, et al. Among authors: nakayama i. Int J Clin Oncol. 2023 Sep;28(9):1191-1199. doi: 10.1007/s10147-023-02370-6. Epub 2023 Jun 22. Int J Clin Oncol. 2023. PMID: 37349660
Safety, tolerability, and efficacy of oxaliplatin-based adjuvant chemotherapy after curative resection of hepatic or extrahepatic metastases of Stage IV colorectal cancer.
Nakayama I, Suenaga M, Wakatsuki T, Ichimura T, Ozaka M, Takahari D, Shinozaki E, Chin K, Ueno M, Mizunuma N, Yamaguchi T. Nakayama I, et al. Cancer Chemother Pharmacol. 2015 Jul;76(1):133-9. doi: 10.1007/s00280-015-2780-1. Epub 2015 May 21. Cancer Chemother Pharmacol. 2015. PMID: 25994854
Change in clinical outcomes during the transition of adjuvant chemotherapy for stage III colorectal cancer.
Osumi H, Shinozaki E, Suenaga M, Wakatsuki T, Nakayama I, Matsushima T, Ogura M, Ichimura T, Takahari D, Chin K, Nagasaki T, Konishi T, Akiyoshi T, Fujimoto Y, Nagayama S, Fukunaga Y, Ueno M, Yamaguchi K. Osumi H, et al. Among authors: nakayama i. PLoS One. 2017 May 31;12(5):e0176745. doi: 10.1371/journal.pone.0176745. eCollection 2017. PLoS One. 2017. PMID: 28562679 Free PMC article.
Retrospective comparison of S-1 plus cisplatin versus S-1 monotherapy for the treatment of advanced gastric cancer patients with positive peritoneal cytology but without gross peritoneal metastasis.
Nakayama I, Chin K, Matsushima T, Takahari D, Ogura M, Shinozaki E, Suenaga M, Ozaka M, Wakatsuki T, Ichimura T, Hiroki O, Yamaguchi K. Nakayama I, et al. Int J Clin Oncol. 2017 Dec;22(6):1060-1068. doi: 10.1007/s10147-017-1164-4. Epub 2017 Jul 26. Int J Clin Oncol. 2017. PMID: 28748355 Clinical Trial.
A retrospective analysis of ramucirumab monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma.
Murahashi S, Takahari D, Wakatsuki T, Fukuda N, Ichimura T, Ogura M, Ozaka M, Shinozaki E, Nakayama I, Matsushima T, Osumi H, Chin K, Yamaguchi K. Murahashi S, et al. Among authors: nakayama i. Int J Clin Oncol. 2018 Feb;23(1):92-97. doi: 10.1007/s10147-017-1192-0. Epub 2017 Sep 14. Int J Clin Oncol. 2018. PMID: 28913565 Clinical Trial.
Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel.
Fukuda N, Takahari D, Wakatsuki T, Osumi H, Nakayama I, Matsushima T, Ichimura T, Ogura M, Ozaka M, Suenaga M, Shinozaki E, Chin K, Yamaguchi K. Fukuda N, et al. Among authors: nakayama i. Oncotarget. 2018 Mar 8;9(20):15219-15227. doi: 10.18632/oncotarget.24635. eCollection 2018 Mar 16. Oncotarget. 2018. PMID: 29632638 Free PMC article.
Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer.
Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K. Wakatsuki T, et al. Among authors: nakayama i. J Gastroenterol. 2018 Nov;53(11):1186-1195. doi: 10.1007/s00535-018-1464-0. Epub 2018 Apr 9. J Gastroenterol. 2018. PMID: 29633013 Free PMC article.
Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
Osumi H, Shinozaki E, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Miki Y, Yamaguchi K. Osumi H, et al. Among authors: nakayama i. Cancer Sci. 2018 Aug;109(8):2567-2575. doi: 10.1111/cas.13698. Epub 2018 Jul 13. Cancer Sci. 2018. PMID: 29908105 Free PMC article. Clinical Trial.
368 results